Unresectable Esophageal Squamous Cell Carcinoma research hub

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy

This study looks at new treatments for cancer of the gullet (oesophagus) that cannot be removed by surgery. Researchers want to see if using immunotherapy drugs, called atezolizumab and tiragolumab, after standard chemotherapy and radiotherapy can help stop the cancer from returning and help people live longer.